Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2023-04-28 Report Publication Anno…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech Holding ASA: Annual Report 2022
Report Publication Announcement Classification · 100% confidence The document explicitly states 'PCI Biotech Holding ASA: Annual Report 2022' in the title and body. It announces that the Board of Directors has approved the 'Annual Report 2022' and states that the report is 'attached'. Given the very short document length (735 chars) and the nature of the announcement (stating the report is attached/published rather than containing the full report content), this fits the definition of a Report Publication Announcement (RPA) according to Rule #2 (The 'MENU VS MEAL' Rule). Although the content is about the Annual Report, the document itself is the announcement of its publication.
2023-04-28 English
PCI Biotech interim Q4 2022 results
Investor Presentation Classification · 95% confidence The document is titled 'PCI Biotech - Q4 2022 Interim Report' and is explicitly labeled as a presentation for February 17, 2023. It contains operational reviews, strategic outlooks, and key financial tables (Q4 2022 vs Q4 2021). While it is a presentation, it provides substantive financial and operational data for a specific interim period (Q4 2022), which aligns with the definition of an Investor Presentation (IP) that includes financial results, rather than a standalone quarterly report (IR) or a simple earnings release (ER). Given the visual slide-deck format and the focus on investor communication, 'IP' is the most accurate classification. Q4 2022
2023-02-17 English
PCI Biotech interim Q4 2022 results
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FOURTH QUARTER AND PRELIMINARY FULL YEAR REPORT' and contains detailed financial tables (Key figures for Q4 and FY), operational reviews, and pipeline updates. It is a comprehensive financial report for a period shorter than a full fiscal year (Q4) and includes the preliminary full-year results, fitting the definition of an Interim/Quarterly Report (IR). Q4 2022
2023-02-17 English
PCI Biotech interim Q4 2022 results
Report Publication Announcement Classification · 99% confidence The document explicitly announces the 'interim Q4 2022 results' for PCI Biotech. It provides key highlights, corporate updates, and details about an accompanying webcast and Q&A session. The text states, 'Please find enclosed the report and presentation.' Furthermore, it mentions that the interim report and presentation will be available on newsweb.no and the company's webpage. This structure—announcing period results and directing users to the full report/presentation—is characteristic of an Earnings Release (ER) or a document preceding a full Interim Report (IR). Since it contains significant operational and financial highlights but directs to the full report, it leans towards an Earnings Release (ER). However, the document is quite detailed and covers the full quarter's performance summary, which often overlaps with the content of an Interim Report (IR). Given the explicit mention of 'interim Q4 2022 results' and the comprehensive nature of the highlights, classifying it as an Interim / Quarterly Report (IR) is appropriate, as it summarizes the period's performance, even if it's an announcement of the release. The document length (6325 chars) is substantial enough to contain more than just a brief announcement, supporting the IR classification over a simple RPA/ER.
2023-02-17 English
PCI Biotech: Invitation to Q4 2022 results presentation
Report Publication Announcement Classification · 98% confidence The document is titled "PCI Biotech: Invitation to Q4 2022 results presentation" and explicitly states that the company invites stakeholders to an online presentation of its "Q4 2022 interim report." It details the time, date, and format of this presentation, and mentions that the interim report and presentation will be made available on the same day. Since the document's primary function is to announce the upcoming release and presentation of a periodic financial report (the Q4 interim report), it fits the definition of a Report Publication Announcement (RPA). It is not the interim report itself (IR), nor is it the full annual report (10-K). The document length (3034 chars) is short, supporting the RPA classification based on the 'MENU VS MEAL' rule.
2023-02-13 English
Flaggemelding relatert til PCIB
Director's Dealing Classification · 95% confidence The document text is very short (458 characters) and describes a transaction where an entity (Myrlid AS) sold shares in PCI Biotech Holding ASA. It explicitly details the number of shares sold and the resulting total ownership percentage (4.95%). This content directly relates to insider trading or significant shareholder transactions, which falls under the 'Director's Dealing' (DIRS) or 'Major Shareholding Notification' (MRQ) categories. Since it details a specific transaction by an associated party (likely a director or major shareholder, given the context of such filings), and it is a notification of a change in holding, MRQ (Major Shareholding Notification) is the most appropriate fit, as the resulting ownership (4.95%) is a significant threshold notification, even if it's below the typical 5% mark often reported, or DIRS if the seller is a director. Given the nature of reporting ownership changes after a transaction, MRQ is highly relevant. However, DIRS specifically covers personal share transactions by directors/executives. Without explicit confirmation that Myrlid AS is a director, MRQ (notification of change in significant share ownership) is a strong candidate, but DIRS often covers transactions by related parties of management/directors. Given the explicit reporting of the transaction and resulting percentage, and the commonality of these reports being classified as insider transactions, I will lean towards DIRS as it captures the 'dealing' aspect by an insider-related party, or MRQ for the resulting holding change. Since the text focuses on the *transaction* and the *resulting holding*, MRQ is slightly more precise for reporting ownership thresholds being crossed or maintained at a significant level. Let's re-evaluate: DIRS is for 'Director's Dealing'. MRQ is for 'Major Shareholding Notification'. Since the resulting holding is 4.95%, it's just under a typical 5% major holding threshold, but the document is a notification of a transaction ('solgt 450 000 aksjer'). In many jurisdictions, transactions by directors/executives are classified as DIRS regardless of the resulting percentage, while MRQ is for crossing specific major ownership thresholds (often 5% or 10%). Given the brevity and focus on the sale by an entity related to the company, DIRS is a very strong fit for insider dealing notification.
2023-01-20 Norwegian

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.